Page 13«..10..12131415..2030..»

Category Archives: Global News Feed

Arcutis and Padagis Agree to Stay Patent Lawsuit

Posted: April 3, 2025 at 2:45 am

WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (Padagis) have requested a stay to the ongoing patent litigation between Padagis and the Company, and the Company has agreed to enter a joint stipulation to stay the case, which was filed in the U.S. District Court for the District of Delaware on April 2, 2025. After the Court enters the joint stipulation, all calendared dates and trial for the patent litigation will be vacated.

Read more here:
Arcutis and Padagis Agree to Stay Patent Lawsuit

Posted in Global News Feed | Comments Off on Arcutis and Padagis Agree to Stay Patent Lawsuit

Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis

Posted: April 3, 2025 at 2:45 am

Basel, 02 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 mg dose in people with relapsing multiple sclerosis (RMS) did not meet its primary endpoint in showing additional benefit in slowing disability progression, as measured by a composite disability endpoint over a period of at least 120 weeks of treatment. The rates of disability progression were low and consistent with rates observed in the previous pivotal studies of OCREVUS IV 600 mg. In addition, in several predefined analyses on disease activity, OCREVUS IV 600 mg showed clinically meaningful results with the lowest annualised relapse rate (ARR) observed during the double-blind period of a Phase III study in RMS. The MUSETTE data further support the efficacy and safety profile of the currently approved OCREVUS IV 600 mg dose for RMS.

Read the rest here:
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis

Posted in Global News Feed | Comments Off on Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Posted: April 3, 2025 at 2:45 am

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on April 1, 2025 the Company granted restricted stock units (RSUs) representing 32,200 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

View original post here:
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Posted in Global News Feed | Comments Off on Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference

Posted: April 3, 2025 at 2:45 am

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET.

Follow this link:
BioCryst to Present at Upcoming Investor Conference

Posted in Global News Feed | Comments Off on BioCryst to Present at Upcoming Investor Conference

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Posted: April 3, 2025 at 2:45 am

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.

The rest is here:
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Posted in Global News Feed | Comments Off on FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Posted: April 3, 2025 at 2:45 am

FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.

Excerpt from:
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Posted in Global News Feed | Comments Off on Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

eXoZymes Provides Fourth Quarter and Full Year 2024 Update

Posted: April 3, 2025 at 2:45 am

Management to Host Conference Call Today at 4:30PM Eastern

Original post:
eXoZymes Provides Fourth Quarter and Full Year 2024 Update

Posted in Global News Feed | Comments Off on eXoZymes Provides Fourth Quarter and Full Year 2024 Update

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Posted: April 3, 2025 at 2:45 am

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors.

Read the rest here:
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Posted in Global News Feed | Comments Off on Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Posted: April 3, 2025 at 2:45 am

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.

Read more:
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Posted in Global News Feed | Comments Off on Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Posted: April 3, 2025 at 2:45 am

PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it is initiating Investigational Product use of Re-Tain®.

Read the original:
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Posted in Global News Feed | Comments Off on ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Page 13«..10..12131415..2030..»